Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022077 | 0.84 | PDE10A (0.63) | PDE10AMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL15022253 | 0.83 | PDE10A (0.61) | PDE10AMAPK14TGFBR1MEN1KMT2A | |
| SCHEMBL30122927 | 0.80 | PDE10A (1.00) | PDE10AMAPK14TGFBR1MEN1KMT2A | |
| SCHEMBL15734191 | 0.80 | PDE10A (1.00) | PDE10AMAPK14TGFBR1MEN1KMT2A | |
| SCHEMBL15022323 | 0.78 | MAPK14 (0.58) | PDE10AMAPK14TGFBR1MEN1KMT2A | |
| SCHEMBL673162 | 0.77 | APP (0.55) | MEN1KMT2A | |
| SCHEMBL15022257 | 0.76 | PDE10A (0.71) | PDE10AMAPK14TGFBR1PDE4APDE4B | |
| SCHEMBL714294 | 0.75 | APP (0.59) | MEN1KMT2A | |
| SCHEMBL15022260 | 0.74 | MAP4K4 (0.66) | PDE10AMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL7780565 | 0.74 | PTGS2 (0.56) | PDE10AMAPK14TGFBR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | PDE10A 5/4885MAPK14 3170/4885TGFBR1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.